Research and Markets has announced the addition of the "MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2016" report to their offering.

MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 Overview
  3. Therapeutics Development
  4. Pipeline Products for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Overview
  5. Pipeline Products for MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Comparative Analysis
  6. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Therapeutics under Development by Companies
  7. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Therapeutics under Investigation by Universities/Institutes
  8. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Products under Development by Companies
  13. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Products under Investigation by Universities/Institutes
  14. MAP Kinase Interacting Serine/Threonine Protein Kinase 2 - Companies Involved in Therapeutics Development

- eFFECTOR Therapeutics Inc

- Eli Lilly and Company

- Merck & Co Inc

- Oncodesign SA

For more information about this report visit http://www.researchandmarkets.com/research/tkkvlb/map_kinase